The White House Declares September as National Prostate Cancer Awareness Month
The White House Office of the Press Secretary For Immediate Release September 01, 2011 Presidential Proclamation — National Prostate Cancer Awareness Month […]
New Data on Long-Term Use of Firmagon® (degarelix) For Men with Advanced Hormone Dependant Prostate Cancer
New data, published September 1 in the Journal of Urology, shows that Firmagon® (degarelix) which is a gonadotropin-releasing hormone therapy (GnRH) given to men with advanced prostate cancer may be superior to leuprolide when used over three years. This new study (CS21A) was an open-label extension of the Phase III study (CS21) in which Firmagon® [...]
Light A Blue Light Bulb for Prostate Cancer Awareness Month – September
Light a Blue Bulb for Prostate Cancer Awareness Month, September 2011. This year, let’s take prostate cancer awareness building into our own hands. Light a Blue Bulb every night (or, for a few nights) during September. […]
Cabozantinib, Promising, Still Controversial For the Treatment of Bone Mets in Prostate Cancer
Cabozantinib (cabo), has many of us prostate cancer survivor, educators and researchers simply scratching their heads. In trials, Cabozantinib demonstrated what some people have characterized as mind boggling activity against bone metastases. In trials the drug led to partial or complete resolution of bone scans in a substantial portion of patients with cancer, including prostate, [...]
A Goal Date for the Possible FDA Approval of Xgeva® (Denosumab) for men with Advanced Prostate Cancer
Amgen (NASDAQ: AMGN) today published a press release that said the U.S. Food and Drug Administration (FDA) will target an action date of April 26, 2012 for the supplemental Biologics License Application (sBLA) (approval) to expand the indication for XGEVA® (denosumab) to treat men with castrate-resistant prostate cancer with the goal of reducing the risk [...]